Title:
標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
Document Type and Number:
Japanese Patent JP2014509197
Kind Code:
A
Abstract:
Provided is an oncolytic adenovirus Ad-TD-hIL12 for target therapy of human tumor, which is deposited in China Center for Type Culture Collection with an accession number CCTCC NO: V201031. The viral vector is C-subclass type 5 adenovirus Ads, which has three genes E1A-CR2, E1B19K and E3gp-19K deleted, and expresses p35 and p40 subgroup gene sequences of human IL12 under the control of the E3gp-19K promoter. Oncolytic cells are replicated in tumor cells by infecting the tumor cells with the viruses, and at the same time, hIL2 having a variety of anti-tumor effects is produced in the tumor tissue at a high level. hIL12 has the effect of anti-tumor angiogenesis, can regulate the body's immunity to make the body produce specific anti-tumor immunity, kill distant metastatic tumor cells, and prevent tumor recurrence. The viral vector of the present invention can be used as a targeting genetic engineering drug for treating various solid tumors, not only can be used for intratumoral injection, can also be used for intraperitoneal and intrathoracic injection, without causing significant side effects, thus having better efficacy and safety.
Inventors:
Wang
Kangoku Tadashi
King Peng Shu
Takafuyu Rei
Lai Meng/Nakatsu
Kangoku Tadashi
King Peng Shu
Takafuyu Rei
Lai Meng/Nakatsu
Application Number:
JP2013555736A
Publication Date:
April 17, 2014
Filing Date:
February 29, 2012
Export Citation:
Assignee:
Beijing Weight Special Biological Technology Co., Ltd.
International Classes:
C12N7/00; A61K35/76; A61P35/00; C12N15/09
Domestic Patent References:
| JP2006511212A | 2006-04-06 |
Foreign References:
| CN102174479A | 2011-09-07 | |||
| WO2007057368A1 | 2007-05-24 | |||
| WO2009048560A1 | 2009-04-16 | |||
| WO2007068772A1 | 2007-06-21 | |||
| CN101643750B | 2010-11-10 | |||
| WO2009048560A1 | 2009-04-16 |
Other References:
JPN6014051136; Ｗｏｎｇ Ｈ．Ｈ． ｅｔ ａｌ．: Ｖｉｒｕｓｅｓ Ｖｏｌ．２， Ｎｏ．１, 2010, ｐｐ．７８-１０６
JPN6014051139; Ｑｉａｏ Ｊ． ｅｔ ａｌ．: Ｃａｎｃｅｒ Ｇｅｎｅ Ｔｈｅｒａｐｙ Ｖｏｌ．６， Ｎｏ．４, 1999, ｐｐ．３７３-３７９
JPN6014051136; Ｗｏｎｇ Ｈ．Ｈ． ｅｔ ａｌ．: Ｖｉｒｕｓｅｓ Ｖｏｌ．２， Ｎｏ．１, 2010, ｐｐ．７８-１０６
JPN6014051139; Ｑｉａｏ Ｊ． ｅｔ ａｌ．: Ｃａｎｃｅｒ Ｇｅｎｅ Ｔｈｅｒａｐｙ Ｖｏｌ．６， Ｎｏ．４, 1999, ｐｐ．３７３-３７９
JPN6015040112; Ｊ． Ｃｌｉｎ． Ｏｎｃｏｌ．， ２００４， Ｖｏｌ． ２２， Ｎｏ． ８， ｐｐ． １３８９-１３９７
JPN6015040115; Ｍｏｌ． Ｔｈｅｒ．， ２００９， Ｖｏｌ． １７， Ｎｏ． ４， ｐｐ． ６１４-６２２
JPN6014051139; Ｑｉａｏ Ｊ． ｅｔ ａｌ．: Ｃａｎｃｅｒ Ｇｅｎｅ Ｔｈｅｒａｐｙ Ｖｏｌ．６， Ｎｏ．４, 1999, ｐｐ．３７３-３７９
JPN6014051136; Ｗｏｎｇ Ｈ．Ｈ． ｅｔ ａｌ．: Ｖｉｒｕｓｅｓ Ｖｏｌ．２， Ｎｏ．１, 2010, ｐｐ．７８-１０６
JPN6014051139; Ｑｉａｏ Ｊ． ｅｔ ａｌ．: Ｃａｎｃｅｒ Ｇｅｎｅ Ｔｈｅｒａｐｙ Ｖｏｌ．６， Ｎｏ．４, 1999, ｐｐ．３７３-３７９
JPN6015040112; Ｊ． Ｃｌｉｎ． Ｏｎｃｏｌ．， ２００４， Ｖｏｌ． ２２， Ｎｏ． ８， ｐｐ． １３８９-１３９７
JPN6015040115; Ｍｏｌ． Ｔｈｅｒ．， ２００９， Ｖｏｌ． １７， Ｎｏ． ４， ｐｐ． ６１４-６２２
Attorney, Agent or Firm:
Takahiro Ozaki